1. Home
  2. KPTI vs STKS Comparison

KPTI vs STKS Comparison

Compare KPTI & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • STKS
  • Stock Information
  • Founded
  • KPTI 2008
  • STKS 2004
  • Country
  • KPTI United States
  • STKS United States
  • Employees
  • KPTI N/A
  • STKS N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • STKS Restaurants
  • Sector
  • KPTI Health Care
  • STKS Consumer Discretionary
  • Exchange
  • KPTI Nasdaq
  • STKS Nasdaq
  • Market Cap
  • KPTI 90.7M
  • STKS 105.2M
  • IPO Year
  • KPTI 2013
  • STKS N/A
  • Fundamental
  • Price
  • KPTI $0.62
  • STKS $3.63
  • Analyst Decision
  • KPTI Strong Buy
  • STKS Buy
  • Analyst Count
  • KPTI 4
  • STKS 3
  • Target Price
  • KPTI $5.00
  • STKS $5.83
  • AVG Volume (30 Days)
  • KPTI 676.1K
  • STKS 105.9K
  • Earning Date
  • KPTI 02-27-2025
  • STKS 03-13-2025
  • Dividend Yield
  • KPTI N/A
  • STKS N/A
  • EPS Growth
  • KPTI N/A
  • STKS N/A
  • EPS
  • KPTI N/A
  • STKS N/A
  • Revenue
  • KPTI $148,442,000.00
  • STKS $541,400,000.00
  • Revenue This Year
  • KPTI $5.47
  • STKS $104.28
  • Revenue Next Year
  • KPTI $6.33
  • STKS $27.24
  • P/E Ratio
  • KPTI N/A
  • STKS N/A
  • Revenue Growth
  • KPTI 1.77
  • STKS 63.49
  • 52 Week Low
  • KPTI $0.58
  • STKS $2.68
  • 52 Week High
  • KPTI $1.95
  • STKS $6.10
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 40.06
  • STKS 61.76
  • Support Level
  • KPTI $0.65
  • STKS $3.53
  • Resistance Level
  • KPTI $0.70
  • STKS $3.98
  • Average True Range (ATR)
  • KPTI 0.05
  • STKS 0.20
  • MACD
  • KPTI -0.00
  • STKS 0.03
  • Stochastic Oscillator
  • KPTI 11.00
  • STKS 66.25

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About STKS The ONE Group Hospitality Inc.

The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.

Share on Social Networks: